C2N Diagnostics and Eisai Inc. announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School...
